Werewolf Therapeutics Files Routine 8-K for Disclosure & Exhibits

Ticker: HOWL · Form: 8-K · Filed: Jan 8, 2024 · CIK: 1785530

Werewolf Therapeutics, Inc. 8-K Filing Summary
FieldDetail
CompanyWerewolf Therapeutics, Inc. (HOWL)
Form Type8-K
Filed DateJan 8, 2024
Risk Levellow
Pages2
Reading Time2 min
Key Dollar Amounts$0.0001
Sentimentneutral

Complexity: simple

Sentiment: neutral

Topics: regulation-fd, compliance, exhibits

TL;DR

**Werewolf Therapeutics filed a standard 8-K, mostly routine compliance.**

AI Summary

Werewolf Therapeutics, Inc. filed an 8-K on January 8, 2024, primarily to disclose information under Regulation FD and to provide financial statements and exhibits. This filing indicates that the company, trading under the symbol HOWL on The Nasdaq Global Select Market, is providing routine updates to the market. For investors, this matters because it signals ongoing compliance and transparency, which are crucial for maintaining investor confidence, though this specific filing doesn't reveal new material financial or operational changes.

Why It Matters

This filing demonstrates Werewolf Therapeutics' ongoing commitment to regulatory compliance and transparency, which is fundamental for investor trust and market stability.

Risk Assessment

Risk Level: low — This 8-K is a routine filing for Regulation FD disclosure and exhibits, indicating no immediate new risks or significant changes.

Analyst Insight

A smart investor would note this as a routine compliance filing, indicating no immediate new material information that would warrant a change in investment strategy. It's a 'check the box' filing, not a catalyst.

Key Numbers

  • 001-40366 — Commission File Number (identifies the company's registration with the SEC)
  • 82-3523180 — IRS Employer Identification No. (identifies the company for tax purposes)
  • 2024-01-08 — Date of Report (indicates when the earliest event reported in the filing occurred)
  • $0.0001 — Par Value per Share (the nominal value of each common stock share)

Key Players & Entities

  • Werewolf Therapeutics, Inc. (company) — the registrant filing the 8-K
  • HOWL (company) — trading symbol for Werewolf Therapeutics, Inc.
  • The Nasdaq Global Select Market (company) — exchange where Werewolf Therapeutics' common stock is registered
  • January 8, 2024 (date) — date of earliest event reported and filing date
  • $0.0001 (dollar_amount) — par value per share of common stock

FAQ

What is the primary purpose of this 8-K filing by Werewolf Therapeutics, Inc.?

The primary purpose of this 8-K filing by Werewolf Therapeutics, Inc. is to satisfy disclosure requirements under Regulation FD and to provide financial statements and exhibits, as indicated by 'ITEM INFORMATION: Regulation FD Disclosure' and 'ITEM INFORMATION: Financial Statements and Exhibits'.

On what date was the earliest event reported in this 8-K filing?

The earliest event reported in this 8-K filing occurred on January 8, 2024, as stated under 'Date of Report (Date of earliest event reported): January 8, 2024'.

What is the trading symbol and the exchange where Werewolf Therapeutics, Inc.'s common stock is registered?

Werewolf Therapeutics, Inc.'s common stock trades under the symbol HOWL and is registered on The Nasdaq Global Select Market, as specified under 'Title of each class' and 'Name of each exchange on which registered'.

What is the state of incorporation for Werewolf Therapeutics, Inc.?

Werewolf Therapeutics, Inc. is incorporated in Delaware, as indicated by 'Delaware (State or Other Jurisdiction of Incorporation)'.

What is the business address and phone number of Werewolf Therapeutics, Inc.?

The business address for Werewolf Therapeutics, Inc. is 200 Talcott Ave, 2nd Floor, Watertown, Massachusetts, 02472, and their telephone number is (617) 952-0555, as listed in the 'BUSINESS ADDRESS' and 'Registrant’s telephone number, including area code' sections.

Filing Stats: 552 words · 2 min read · ~2 pages · Grade level 10.6 · Accepted 2024-01-08 08:08:05

Key Financial Figures

  • $0.0001 — nge on which registered Common Stock, $0.0001 par value per share HOWL The Nasdaq

Filing Documents

01

Item 7.01. Regulation FD Disclosure On January 8, 2024, Werewolf Therapeutics, Inc. (the "Company") issued a press release to provide a business update and highlight the Company's 2024 strategy outlook. A copy of the press release is furnished as Exhibit 99.1 hereto and is incorporated herein by reference. Also on January 8, 2024, the Company made publicly available on its website an updated corporate presentation. A copy of the presentation is furnished as Exhibit 99.2 hereto and is incorporated herein by reference. The information furnished under this Item 7.01, including Exhibits 99.1 and 99.2, shall not be deemed "filed" for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as expressly set forth by specific reference in such a filing.

Financial Statements and Exhibits

Financial Statements and Exhibits. (d) Exhibits Exhibit No. Description 99.1 Press Release, dated January 8, 2024 99.2 Investor Presentation, dated January 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL document)

SIGNATURES

SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. WEREWOLF THERAPEUTICS, INC. Date: January 8, 2024 By: /s/ Timothy W. Trost Timothy W. Trost Chief Financial Officer and Treasurer

View Full Filing

View this 8-K filing on SEC EDGAR

View on ReadTheFiling | About | Contact | Privacy | Terms

Data from SEC EDGAR. Not affiliated with the SEC. Not investment advice. © 2026 OpenDataHQ.